Tofacitinib, a JAK inhibitor (JAKi) that predominantly inhibits JAK1 and JAK3 molecules has been shown to ameliorate aortitis due to GCA by inhibiting the action of T lymphocytes [119]. This evidence concerns the gene JAK3 and temporal arteritis.